The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
An article from
Dive Brief
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
Published June 25, 2026
By
Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader
Zymeworks to acquire troubled biotech Theravance in $929M deal
Zymeworks acquires struggling Theravance for $929M
Another big deal, another sign biotech M&A is back
Gene-editing startup launches with $230 million and a Chinese licensing deal
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition - Theravance Biopharma (NASDAQ
Boundless Bio's reverse merger; CARsgen wins first solid tumor approval for CAR-T
Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as…
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before…
Zymeworks to acquire Theravance Biopharma for $929M, gaining rights to COPD drug Yupelri's US profit share and ex-US royalties…
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired…
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
The medical biotechnology and pharmaceutical investment market was always very risk averse, giving rise to the valley of death…
